WHO Expert Committee on Selection and Use of Essential Medicines Has Met Nearly Every Two Years Since It Was fi Rst Established in 1977

Total Page:16

File Type:pdf, Size:1020Kb

WHO Expert Committee on Selection and Use of Essential Medicines Has Met Nearly Every Two Years Since It Was fi Rst Established in 1977 WHO Technical Report Series 946 THE This report presents the recommendations of the WHO Expert SELECTION THE SELECTION AND USE Committee responsible for updating the WHO Model List of Essential Medicines. The fi rst part contains a summary of the Committee’s OF ESSENTIAL MEDICINES considerations and justifi cations for additions and changes to the Model List, including its recommendations. Annexes to the main report include the revised version of the WHO Model List of Essential AND Medicines (the 15th) and a list of all items on the Model List sorted according to their 5-level Anatomical Therapeutic Chemical (ATC) USE classifi cation codes. Other annexes cover the proposed procedure for updating and disseminating the WHO Model List of Essential OF Medicines, and the revised procedure for updating the content ESSENTIAL of the Interagency Emergency Health Kit. Report of the WHO Expert Committee, 2007 MEDICINES (including the 15th Model List of Essential Medicines) WHO Technical Report ISBN 9789241209465 Series — 946 TRS946 cover.indd 1 28.11.2007 11:57:32 The World Health Organization was established in 1948 as a specialized agency of the United Nations serving as the directing and coordinating authority for SELECTED WHO PUBLICATIONS OF RELATED INTEREST international health matters and public health. One of WHO’s constitutional functions is to provide objective and reliable information and advice in the The international pharmacopoeia, fourth edition. fi eld of human health, a responsibility that it fulfi ls in part through its extensive Volume 1: general notices; monographs for pharmaceutical substances (A–O) programme of publications. The Organization seeks through its publications Volume 2: monographs for pharmaceutical substances (P–Z); monographs for dosage to support national health strategies and address the most pressing public health concerns of populations around the world. To respond to the needs of forms and radiopharmaceutical preparations; methods of analysis; reagents. Member States at all levels of development, WHO publishes practical manuals, 2006 (1500 pages), also available in CD-ROM format handbooks and training material for specifi c categories of health workers; inter- nationally applicable guidelines and standards; reviews and analyses of health Basic tests for drugs: pharmaceutical substances, policies, programmes and research; and state-of-the-art consensus reports that medicinal plant materials and dosage forms offer technical advice and recommendations for decision-makers. These books 1998 (94 pages) are closely tied to the Organization’s priority activities, encompassing disease prevention and control, the development of equitable health systems based Basic tests for pharmaceutical dosage forms on primary health care, and health promotion for individuals and communities. 1991 (134 pages) Progress towards better health for all also demands the global dissemination and exchange of information that draws on the knowledge and experience of Quality assurance of pharmaceuticals: a compendium all WHO’s Member countries and the collaboration of world leaders in public of guidelines and related materials. health and the biomedical sciences. To ensure the widest possible availability Volume 1: 1997 (244 pages) of authoritative information and guidance on health matters, WHO secures the Volume 2: Good manufacturing practices and inspection. broad international distribution of its publications and encourages their trans- 2nd updated edition, 2007 (in press) lation and adaptation. By helping to promote and protect health and prevent and control disease throughout the world, WHO’s books contribute to achieving the Quality control methods for medicinal plant materials Organization’s principal objective — the attainment by all people of the highest 1998 (123 pages) possible level of health. WHO Expert Committee on Specifi cations for Pharmaceutical Preparations Forty-fi rst report. WHO Technical Report Series, No. 943, 2007 (156 pages) The WHO Technical Report Series makes available the findings of various international groups of experts that provide WHO with the latest scientific International nonproprietary names (INN) for pharmaceutical substances. and technical advice on a broad range of medical and public health sub- Cumulative list no. 11. jects. Members of such expert groups serve without remuneration in their 2004 (available in CD-ROM format only) personal capacities rather than as representatives of governments or other bodies; their views do not necessarily reflect the decisions or the stated WHO Expert Committee on Biological Standardization policy of WHO. An annual subscription to this series, comprising about six Fifty-fi fth report. such reports, costs CHF 168.00/US$ 151.00 (CHF 128.40/US$ 115.00 in WHO Technical Report Series, No. 932, 2006 (146 pages) developing countries). For further information, please contact: WHO Press, World Health Organization, 20 avenue Appia, 1211 Geneva 27, Switzerland WHO model formulary (tel. +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]; 2006 (available in CD-ROM format only) order on line: http://www.who.int/bookorders). Further information on these and other WHO publications can be obtained from WHO Press, World Health Organization, 1211 Geneva 27, Switzerland (tel. +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]; order on line: http://www.who.int/bookorders) TRS946 cover.indd 2 28.11.2007 11:57:11:57:3333 This report contains the collective views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization WHO Technical Report Series 946 THE SELECTION AND USE OF ESSENTIAL MEDICINES Report of the WHO Expert Committee, 2007 (including the 15th Model List of Essential Medicines) Geneva 2007 WHO Library Cataloguing-in-Publication DataPublications of the World Health Organization enjoy copyright protection in accordance with the WHO Library Cataloguing-in-Publication Data WHO Expert Committee on the Selection and Use of Essential Medicines (15th: 2007: Geneva, Switzerland) The selection and use of essential medicines: report of the WHO Expert Committee, 2007: (including the 15th model list of essential medicines). (WHO technical report series; no. 946) 1. Essential drugs - standards. 2. Formularies - standards. 3. Drug information services - organization and administration. 4. Drug utilization. 5. Pharmaceutical preparations - classifi cation. 6. Guidelines. I. Title. II. Title: 15th model list of essential medicines. III. Series. ISBN 978 92 4 120946 5 (LC/NLM classifi cation: QV 55) ISSN 0512-3054 © World Health Organization 2007 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications — whether for sale or for noncommercial distribution — should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specifi c companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters. All reasonable precautions have been taken by the World Health Organization to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall the World Health Organization be liable for damages arising from its use. This publication contains the collective views of an international group of experts and does not necessarily represent the decisions or the stated policy of the World Health Organization. Typeset in Switzerland Printed in Switzerland Contents 1. Introduction 1 2. Open session 2 3. Update on current activities 4 3.1 Procedure to update and disseminate the Model List 4 3.2 Proposal for subcommittee on essential medicines for children 6 3.3 Proposal on listing fi xed-dose combination products for infectious diseases 8 3.4 Report from the Advisory Committee on Safety of Medicinal Products 10 3.5 Update of dosage forms and strengths for products on the Model List 10 3.6 Rare diseases proposal 12 3.7 Procedure for updating the content of the Interagency Emergency Health Kit 13 3.8 Late agenda item on medicines for acute care 14 3.9 Report on WHO Model Formulary 14 3.10 Report on Drug Bulletin manual 15 3.11 Review of proposal regarding critically important antibiotics 15 3.12 Advice on draft resolution on rational use of medicines 16 4. Changes made in revising the Model List by section: medicines for all populations 18 4.1 Section 2: addition of prolonged-release morphine 18 4.2 Section 6.1: deletion
Recommended publications
  • (12) United States Patent (10) Patent No.: US 8,993,581 B2 Perrine Et Al
    US00899.3581B2 (12) United States Patent (10) Patent No.: US 8,993,581 B2 Perrine et al. (45) Date of Patent: Mar. 31, 2015 (54) METHODS FOR TREATINGVIRAL (58) Field of Classification Search DSORDERS CPC ... A61K 31/00; A61K 31/166; A61K 31/185: A61K 31/233; A61K 31/522: A61K 38/12: (71) Applicant: Trustees of Boston University, Boston, A61K 38/15: A61K 45/06 MA (US) USPC ........... 514/263.38, 21.1, 557, 565, 575, 617; 424/2011 (72) Inventors: Susan Perrine, Weston, MA (US); Douglas Faller, Weston, MA (US) See application file for complete search history. (73) Assignee: Trustees of Boston University, Boston, (56) References Cited MA (US) U.S. PATENT DOCUMENTS (*) Notice: Subject to any disclaimer, the term of this 3,471,513 A 10, 1969 Chinn et al. patent is extended or adjusted under 35 3,904,612 A 9/1975 Nagasawa et al. U.S.C. 154(b) by 0 days. (Continued) (21) Appl. No.: 13/915,092 FOREIGN PATENT DOCUMENTS (22) Filed: Jun. 11, 2013 CA 1209037 A 8, 1986 CA 2303268 A1 4f1995 (65) Prior Publication Data (Continued) US 2014/OO45774 A1 Feb. 13, 2014 OTHER PUBLICATIONS Related U.S. Application Data (63) Continuation of application No. 12/890,042, filed on PCT/US 10/59584 Search Report and Written Opinion mailed Feb. Sep. 24, 2010, now abandoned. 11, 2011. (Continued) (60) Provisional application No. 61/245,529, filed on Sep. 24, 2009, provisional application No. 61/295,663, filed on Jan. 15, 2010. Primary Examiner — Savitha Rao (74) Attorney, Agent, or Firm — Nixon Peabody LLP (51) Int.
    [Show full text]
  • The Impact of a Changed Legislation on Reporting of Adverse Drug Reactions in Sweden, with Focus on Nurses Reporting
    The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses reporting Sofia A. Karlsson, Ingela Jacobsson, Marit Danell Boman, Katja M. Hakkarainen, Henrik Lövborg, Staffan Hägg and Anna K Jönsson Linköping University Post Print N.B.: When citing this work, cite the original article. The original publication is available at www.springerlink.com: Sofia A. Karlsson, Ingela Jacobsson, Marit Danell Boman, Katja M. Hakkarainen, Henrik Lövborg, Staffan Hägg and Anna K Jönsson, The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses reporting, 2015, European Journal of Clinical Pharmacology, (71), 5, 631-636. http://dx.doi.org/10.1007/s00228-015-1839-6 Copyright: Springer Verlag (Germany) http://www.springerlink.com/?MUD=MP Postprint available at: Linköping University Electronic Press http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-118037 The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses’ reporting Sofia A Karlsson1, Ingela Jacobsson2, Marit Danell Boman3, Katja M Hakkarainen4,5, Henrik Lövborg2, Staffan Hägg2,5, Anna K Jönsson2 Affiliations: 1. Department of Public Health and Community Medicine, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden 2. Department of Clinical Pharmacology and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden 3. Division of Clinical Pharmacology, University Hospital of Umeå, Umeå, Sweden 4. Nordic School of
    [Show full text]
  • Assessing the Availability, Service Quality, and Price of Essential Medicines In
    Assessing the Availability, Service Quality, and Price of Essential Medicines in Private Pharmacies in Afghanistan Norio Kasahara A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2015 Reading Committee: Louis P. Garrison, Jr., Chair Joseph B. Babigumira Andy Stergachis Program Authorized to Offer Degree: Pharmaceutical Outcomes Research and Policy ©Copyright 2015 Norio Kasahara ii Table of Contents Abstract ................................................................................................................................................................................... ................................................................................................ ................................................................................................ .................................................................................. ............... vvv Acknowledgements ................................................................................................................................................................................... ................................................................................................ ................................................................................. ............ viiviivii Summary ................................................................................................................................................................................... ...............................................................................................
    [Show full text]
  • Review of Sezary Syndrome
    REVIEWS Sezary syndrome: Immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC) EliseA.Olsen,MD,a Alain H. Rook, MD,b John Zic, MD,c Youn Kim, MD,d PierluigiPorcu,MD,e Christiane Querfeld, MD,f Gary Wood, MD,g Marie-France Demierre, MD,h Mark Pittelkow, MD,i Lynn D. Wilson, MD, MPH,j Lauren Pinter-Brown, MD,k Ranjana Advani, MD,d Sareeta Parker, MD,l Ellen J. Kim, MD,b Jacqueline M. Junkins-Hopkins, MD,m Francine Foss, MD,j Patrick Cacchio, BS,a and Madeleine Duvic, MDn Durham, North Carolina; Philadelphia, Pennsylvania; Nashville, Tennessee; Palo Alto and Los Angeles, California; Columbus, Ohio; Chicago, Illinois;Madison,Wisconsin;Boston,Massachusetts; Rochester, Minnesota; New Haven, Connecticut; Atlanta, Georgia; Baltimore, Maryland; and Houston, Texas Sezary syndrome (SS) has a poor prognosis and few guidelines for optimizing therapy. The US Cutaneous Lymphoma Consortium, to improve clinical care of patients with SS and encourage controlled clinical trials of promising treatments, undertook a review of the published literature on therapeutic options for SS. An overview of the immunopathogenesis and standardized review of potential current treatment options for SS including metabolism, mechanism of action, overall efficacy in mycosis fungoides and SS, and common or concerning adverse effects is first discussed. The specific efficacy of each treatment for SS, both as monotherapy and combination therapy, is then reported using standardized criteria for both SS and response to therapy with the type of study defined by a modification of the US Preventive Services guidelines for evidence-based medicine.
    [Show full text]
  • Reseptregisteret 2013–2017 the Norwegian Prescription Database
    LEGEMIDDELSTATISTIKK 2018:2 Reseptregisteret 2013–2017 Tema: Legemidler og eldre The Norwegian Prescription Database 2013–2017 Topic: Drug use in the elderly Reseptregisteret 2013–2017 Tema: Legemidler og eldre The Norwegian Prescription Database 2013–2017 Topic: Drug use in the elderly Christian Berg Hege Salvesen Blix Olaug Fenne Kari Furu Vidar Hjellvik Kari Jansdotter Husabø Irene Litleskare Marit Rønning Solveig Sakshaug Randi Selmer Anne-Johanne Søgaard Sissel Torheim Utgitt av Folkehelseinstituttet/Published by Norwegian Institute of Public Health Område for Helsedata og digitalisering Avdeling for Legemiddelstatistikk Juni 2018 Tittel/Title: Legemiddelstatistikk 2018:2 Reseptregisteret 2013–2017 / The Norwegian Prescription Database 2013–2017 Forfattere/Authors: Christian Berg, redaktør/editor Hege Salvesen Blix Olaug Fenne Kari Furu Vidar Hjellvik Kari Jansdotter Husabø Irene Litleskare Marit Rønning Solveig Sakshaug Randi Selmer Anne-Johanne Søgaard Sissel Torheim Acknowledgement: Julie D. W. Johansen (English text) Bestilling/Order: Rapporten kan lastes ned som pdf på Folkehelseinstituttets nettsider: www.fhi.no The report can be downloaded from www.fhi.no Grafisk design omslag: Fete Typer Ombrekking: Houston911 Kontaktinformasjon/Contact information: Folkehelseinstituttet/Norwegian Institute of Public Health Postboks 222 Skøyen N-0213 Oslo Tel: +47 21 07 70 00 ISSN: 1890-9647 ISBN: 978-82-8082-926-9 Sitering/Citation: Berg, C (red), Reseptregisteret 2013–2017 [The Norwegian Prescription Database 2013–2017] Legemiddelstatistikk 2018:2, Oslo, Norge: Folkehelseinstituttet, 2018. Tidligere utgaver / Previous editions: 2008: Reseptregisteret 2004–2007 / The Norwegian Prescription Database 2004–2007 2009: Legemiddelstatistikk 2009:2: Reseptregisteret 2004–2008 / The Norwegian Prescription Database 2004–2008 2010: Legemiddelstatistikk 2010:2: Reseptregisteret 2005–2009. Tema: Vanedannende legemidler / The Norwegian Prescription Database 2005–2009.
    [Show full text]
  • Overview of Antiviral Medications Used in Ophthalmology
    ANTIVIRALS Overview of antiviral medications Jeremy Hoffman Clinical Research used in ophthalmology Fellow: International Centre for Eye Health, As eye health professionals, London School of Hygiene & Tropical we are fortunate to have Medicine, UK. a number of antiviral medications available in our armoury to treat a range of ophthalmic viral infections. This article provides an overview of what antiviral agents are available for these conditions, detailing their regimen SANDIP DAS SANYAM (SAGARMATHA CHOUDHARY EYE HOSPITAL, NEPAL) SANDIP DAS SANYAM(SAGARMATHA and evidence that Aciclovir – either as topical eye ointment or systemic tablets – is still the first-line antiviral in the treatment of many viral eye diseases around the supports their use. world, including here in Nepal. phthalmic viral infections, particularly herpes associated with toxicity, including superficial punctate simplex keratitis, have been at the forefront of keratopathy, chemical conjunctivitis, punctal occlusion Othe development of antiviral medications. and occasional serious hypersensitivity reactions. Idoxuridine was also unable to penetrate the corneal The discovery of the first targeted antiviral agent, epithelium to treat stromal or endothelial keratitis. in common with penicillin (the first antibiotic), owes much to serendipity. In 1959, William Prusoff With the advent of aciclovir in 1982, most herpetic developed idoxuridine (IDU) as a potential systemic ophthalmic infections became treatable, including anti-cancer agent. Idoxuridine those caused by herpes
    [Show full text]
  • The Pennsylvania State University
    The Pennsylvania State University The Graduate School Department of Chemistry SYNTHESIS OF NOVEL ANTIVIRAL AGENTS AND FLUORESCENT MOLECULAR PROBES A Dissertation in Chemistry by Runzhi Wu 2010 Runzhi Wu Submitted in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy August 2010 The dissertation of Runzhi Wu was reviewed and approved* by the following: Blake R. Peterson Regents Distinguished Professor of Medicinal Chemistry University of Kansas Dissertation Advisor Special Member of Committee Raymond L. Funk Professor of Chemistry Chair of Committee Phillip C. Bevilacqua Professor of Chemistry Gong Chen Assistant Professor of Chemistry Avery August Distinguished Professor of Immunology Barbara J. Garrison Shapiro Professor of Chemistry Head of the Department of Chemistry *Signatures are on file in the Graduate School iii ABSTRACT RNA viruses cause a wide variety of diseases including SARS, influenza, hepatitis C and polio. Therapeutics for RNA virus infections are often limited because of the rapid development of antiviral drug resistance. RNA viruses are known to exhibit high error rates during replication and thus exist as quasispecies. To maintain the maximum adaptability, these viruses exist on the edge of “error catastrophe”, and small increases in the mutation frequency can cause a drastic decrease in viral infectivity. By taking advantage of the high mutation rate of RNA virus replication, a relatively new antiviral approach termed “lethal mutagenesis” can be used to increase the error rate of RNA viral replication to intolerable levels, resulting in the loss of viral viability. Chapter one of this dissertation reviews current antiviral therapeutics and lethal mutagenesis as an antiviral strategy.
    [Show full text]
  • The Phytochemistry of Cherokee Aromatic Medicinal Plants
    medicines Review The Phytochemistry of Cherokee Aromatic Medicinal Plants William N. Setzer 1,2 1 Department of Chemistry, University of Alabama in Huntsville, Huntsville, AL 35899, USA; [email protected]; Tel.: +1-256-824-6519 2 Aromatic Plant Research Center, 230 N 1200 E, Suite 102, Lehi, UT 84043, USA Received: 25 October 2018; Accepted: 8 November 2018; Published: 12 November 2018 Abstract: Background: Native Americans have had a rich ethnobotanical heritage for treating diseases, ailments, and injuries. Cherokee traditional medicine has provided numerous aromatic and medicinal plants that not only were used by the Cherokee people, but were also adopted for use by European settlers in North America. Methods: The aim of this review was to examine the Cherokee ethnobotanical literature and the published phytochemical investigations on Cherokee medicinal plants and to correlate phytochemical constituents with traditional uses and biological activities. Results: Several Cherokee medicinal plants are still in use today as herbal medicines, including, for example, yarrow (Achillea millefolium), black cohosh (Cimicifuga racemosa), American ginseng (Panax quinquefolius), and blue skullcap (Scutellaria lateriflora). This review presents a summary of the traditional uses, phytochemical constituents, and biological activities of Cherokee aromatic and medicinal plants. Conclusions: The list is not complete, however, as there is still much work needed in phytochemical investigation and pharmacological evaluation of many traditional herbal medicines. Keywords: Cherokee; Native American; traditional herbal medicine; chemical constituents; pharmacology 1. Introduction Natural products have been an important source of medicinal agents throughout history and modern medicine continues to rely on traditional knowledge for treatment of human maladies [1]. Traditional medicines such as Traditional Chinese Medicine [2], Ayurvedic [3], and medicinal plants from Latin America [4] have proven to be rich resources of biologically active compounds and potential new drugs.
    [Show full text]
  • View/Download
    Research Article Research Article Dermatology Research Therapy with Pegylated Interferon or Combined with Cryosurgery in Condyloma Acuminata. Phase III Clinical Trial Israel Alfonso Trujillo*, Tomás Tabilo Bocic, Ángela Rosa Gutiérrez Rojas, Hugo Nodarse Cuní, María Elena Flores Andrade, and María del Carmen Toledo García *Correspondence: Israel Alfonso-Trujillo, Calzada of Managua # 1133 e/Caimán and Quemados. Las Guásimas. Arroyo Naranjo, Havana, Cuba, E-mail: Surgical Clinical Hospital: "Hermanos Ameijeiras", Cuba. [email protected] Received: 04 January 2019; Accepted: 18 February 2019 Citation: Israel Alfonso Trujillo, Tomás Tabilo Bocic, Ángela Rosa Gutiérrez Rojas, et al. Therapy with Pegylated Interferon or Combined with Cryosurgery in Condyloma Acuminata. Phase III Clinical Trial. Dermatol Res. 2019; 1(1); 1-8. ABSTRACT Background: The continuous recurrence of condyloma acuminata makes the constant search for necessary therapeutic alternatives. Patients and method: To evaluate the therapeutic efficacy and safety of pegylated interferon, alone or adjuvant for cryosurgery, in the condyloma acuminata an open clinical trial was carried out on 30 patients of the "Hermanos Ameijeiras" hospital, who were randomized to receive for 6 weeks (group A) only fortnightly cryosurgery, (group B) subcutaneous pegylated interferon, once a week, associated with fortnightly cryosurgery application or (group C) only subcutaneous pegylated interferon, once a week. The main variable was the percentage of recurrence at one year of follow-up, evaluated quarterly. There was also a rigorous control of adverse events. Results: At the end of the treatment 8/10 (80%) patients from group A, 10/10 (100%) from group B and 9/10 (90%) from group C were left without injuries.
    [Show full text]
  • Belayachi Et Al., Afr J Tradit Complement Altern Med. (2017) 14(2):356-373 Doi:10.21010/Ajtcam.V14i2.37
    Belayachi et al., Afr J Tradit Complement Altern Med. (2017) 14(2):356-373 doi:10.21010/ajtcam.v14i2.37 INDUCTION OF CELL CYCLE ARREST AND APOPTOSIS BY ORMENIS ERIOLEPIS A MORROCAN ENDEMIC PLANT IN VARIOUS HUMAN CANCER CELL LINES Lamiae Belayachia,b*, Clara Aceves-Luquerob, Nawel Merghoubd, Silvia Fernández de Mattosb,c, Saaïd a b,c a Amzazi , Priam Villalonga ,Youssef Bakri a Biochemistry-Immunology Laboratory, Faculty of Sciences, Mohammed V-Agdal University, Rabat, Morocco, b Cancer Cell Biology Group, Institut Universitari d’Investigació en Ciències de la Salut (IUNICS), c Departament de Biologia Fonamental, Universitat de les Illes Balears, Illes Balears, Spain, Green Biotechnology Center. MAScIR (Moroccan Foundation for Advanced Science, Innovation & Research)- Rabat Design Center, Rabat - Morocco. *Corresponding author E-mail: [email protected] Abstract Background: Ormenis eriolepis Coss (Asteraceae) is an endemic Moroccan subspecies, traditionally named “Hellala” or “Fergoga”. It’s usually used for its hypoglycemic effect as well as for the treatment of stomacal pain. As far as we know, there is no scientific exploration of anti tumoral activity of Ormenis eriolepis extracts. Materials and Methods: In this regard, we performed a screening of organic extracts and fractions in a panel of both hematological and solid cancer cell lines, to evaluate the potential in vitro anti tumoral activity and to elucidate the respective mechanisms that may be responsible for growth arrest and cell death induction. The plant was extracted using organic solvents, and four different extracts were screened on Jurkat, Jeko-1, TK-6, LN229, SW620, U2OS, PC-3 and NIH3T3 cells. Results: Cell viability assays revealed that, the IC50 values were (11,63±5,37µg/ml) for Jurkat, (13,33±1,67µg/ml) for Jeko-1, (41,67±1,98µg/ml) for LN229 and (19,31±4,88µg/ml) for PC-3 cells upon treatment with Oe-DF and Oe-HE respectively.
    [Show full text]
  • Trifluridine Decreases Ocular HSV-1 Recovery, but Not Herpetlc Lesions After Timolol Iontophoresis
    Investigative Ophthalmology & Visual Science, Vol. 30, No. 4, April 1989 Copyright © Association for Research in Vision and Ophthalmology Trifluridine Decreases Ocular HSV-1 Recovery, but Not Herpetlc Lesions after Timolol Iontophoresis David S. Roorman,* James M. Hill, Yasuteru Harura, James J. Reidy, and Herbert E. Kaufman To determine the effect of a topically applied antiviral agent on shedding of herpes simplex virus type 1 (HSV-1) into the tear film and corneal epithelial lesions, ten rabbits latently infected with HSV-1 were subjected to transcorneal iontophoresis of 0.01% timolol once a day for 3 consecutive days to induce viral shedding and lesions. Iontophoretic induction was performed similarly in five uninfected rabbits as controls. Half of the infected rabbits and all of the uninfected controls received topical 1.0% trifluridine five times a day for 9 days, beginning the day after the first iontophoresis. All eyes were examined daily for 10 days by slit-lamp biomicroscopy and tear film samples collected on swabs were analyzed for virus. In the infected rabbits, the eyes treated with trifluridine had significantly fewer swabs positive for HSV-1 than the untreated eyes (P < 0.001); however, there was no significant difference in the numbers of lesions in the treated and untreated eyes. The uninfected controls had no positive swabs and developed no lesions. These results suggest that topical treatment with trifluridine may reduce recovery of HSV-1 from the tear film, but does not affect the incidence of iontophoretically induced cornea! epithelial lesions. Invest Ophthalmol Vis Sci 30:678-683,1989 Herpes simplex virus type 1 (HSV-1) causes an ini- ing epinephrine iontophoresis with concomitant in- tial ocular infection followed by latency in the auto- travenous and topical acyclovir, as well as a signifi- nomic and sensory ganglia of the head and neck.1"3 cant quantitative reduction in recovery of HSV-1 Stimuli such as fever, UV radiation, stress and radial from the trigeminal ganglia.
    [Show full text]
  • Supplementary Appendix
    Supplementary appendix Sipilä PN, Heikkilä N, Lindbohm JV, Hakulinen C, Vahtera J, Elovainio M, Suominen S, Väänänen A, Koskinen A, Nyberg ST, Pentti J, Strandberg TE, Kivimäki M. Hospital-treated infectious diseases and the risk of incident dementia: multicohort study with replication in the UK Biobank CONTENTS eFigure 1. Selection of participants in the study............................................................................... 2 eMethods 1. Study cohorts and data collection ................................................................................ 3 The Finnish Public Sector study (FPS)......................................................................................... 3 The Health and Social Support study (HeSSup) ........................................................................... 4 The Still Working study (STW) ................................................................................................... 5 The UK Biobank ......................................................................................................................... 5 eMethods 2. Proportionality of hazards ........................................................................................... 7 eFigure 2. Visualisation of hazard ratios over time using exponentiated scaled Schoenfeld residuals ....................................................................................................................................................... 8 eFigure 3. Dementia follow-up .....................................................................................................
    [Show full text]